ADVISORY, Feb. 5, 2014 (GLOBE NEWSWIRE) -- What: Karyopharm Therapeutics Inc. [KPTI], a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, will visit the NASDAQ MarketSite in Times Square.
- Karyopharm completed a successful IPO in November 2013, which raised gross proceeds of over $125M.
- Karyopharm presented data from the Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with heavily pretreated hematologic malignancies at the 2013 American Society of Hematology Annual Meeting showing preliminary evidence of broad anti-cancer activity as an oral, single agent therapy.
- Data were also presented at the American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium from the Phase 1 study of Selinexor showing preliminary evidence of antitumor activity in metastatic colorectal cancer patients whose tumors were progressing at the start of the study.
- Karyopharm expects to initiate registration-directed trials of Selinexor in the first half of 2014.
About NASDAQ OMX Group:NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com. -NDAQA-